-
Sumitomo Pharma’s China CEO Highlights Strategic Importance of Local Market
•
Yoshitaka Koketsu, CEO of Sumitomo Pharma (TYO: 4506) (China) Co., Ltd, the Chinese subsidiary of Japan-based Sumitomo Pharma, has expressed strong optimism about the company’s prospects in the local market in an interview with Shanghai Daily. Koketsu emphasized that China, as the world’s second-largest pharmaceutical market, holds strategic significance for…
-
Health Canada Approves Pfizer and Sumitomo Pharma’s Myfembree for Endometriosis Pain Management
•
Health Canada has granted regulatory approval to Pfizer (NYSE: PFE) and Sumitomo Pharma (TYO: 4506) for their women’s health product Myfembree (relugolix + estradiol + norethindrone acetate). The approval is for the management of moderate-to-severe pain associated with endometriosis in pre-menopausal women, supported by late-stage data from multiple trials. Previous…
